secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0000872589-25-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%
--------------------------------------------------------------------------------

- Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).
- Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.
- FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.
- EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.
- In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/0000872589-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/regn-20250801.htm
  HTML page:      https://secwatch.observer/filing/0000872589-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer